Previous 10 | Next 10 |
Addex Therapeutics Limited (ADXN) Q4 2021 Earnings Conference Call March 10, 2022, 10:00 AM ET Company Participants Tim Dyer - CEO Roger Mills - Chief Medical Officer Robert Lutjens - Head of Discovery Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuat...
Addex Therapeutics press release (NASDAQ:ADXN): FY GAAP EPS of -CHF 0.45. Income decreased to CHF 3.2 million in 2021 compared to CHF 3.9 million in 2020. Cash and cash equivalents increased to CHF 20.5 million at December 31, 2021, compared to CHF 18.7 million at December 31, 2020. Fo...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Addex Therapeutics (NASDAQ:ADXN) has entered into an agreement with Armistice Capital LLC, to sell 3,752,202 shares in the form of 625,367 ADSs at a purchase price of $6.50/ADS, equivalent to CHF1.00/share. Each ADS represents six shares. Additionally, Addex has agreed to issue to A...
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of a class of drugs for neurological disorders. CEO Tim Dyer shared with us its emerging class of drugs called allosteric modulators, which work differently than classical dr...
The following slide deck was published by Addex Therapeutics Ltd in conjunction with their 2021 Q2 earnings call. For further details see: Addex Therapeutics Ltd 2021 Q2 - Results - Earnings Call Presentation
Addex Therapeutics (NASDAQ:ADXN): Q2 GAAP EPS of -CHF0.14. Revenue of CHF1.07M (+18.9% Y/Y) Press Release For further details see: Addex Therapeutics reports Q2 results
Addex Therapeutics (ADXN) has started screening patients for its Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID). The registration program comprises two placebo-controlled studies. The first, Study 301, is a Phase 2b/3 clinical t...
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the thr...
Addex Therapeutics (ADXN) announces that the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 (ADX71149) in patients with epilepsy, being conducted in collaboration with Janssen Pharmaceuticals of Johnson & Johnson (JNJ). Data from the study are expe...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...